...
search icon
prqr-img

ProQR Therapeutics BV Share Price

PRQR
NAQ
$1.455
-$0.03
(-2.01%)
1D
Industry: Biotechnology Sector: Health Care

ProQR Therapeutics BV Analyst Forecast

ProQR Therapeutics BV Share Price Chart

ProQR Therapeutics BV Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$156.96M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
152.64K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.20
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.07 L
$3.1 H
$1.455

About ProQR Therapeutics BV, Common Stock

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. more

Industry: BiotechnologySector: Health Care

ProQR Therapeutics BV Stock Returns

Time FramePRQRSectorS&P500
1-Week Return4.93%0.91%-0.82%
1-Month Return-11.31%1.46%1.28%
3-Month Return-28.37%3.33%3.98%
6-Month Return-29.72%16.03%6.73%
1-Year Return-42.25%9.1%12.24%
3-Year Return-50.66%21.02%72.07%
5-Year Return-68.7%36.15%75.69%
10-Year Return-67.96%138.89%258.38%

ProQR Therapeutics BV Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.03M1.33M3.59M6.51M18.91M[{"date":"2020-12-31","value":5.44,"profit":true},{"date":"2021-12-31","value":7.06,"profit":true},{"date":"2022-12-31","value":19.01,"profit":true},{"date":"2023-12-31","value":34.46,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue2.19M-2.48M133.52K-[{"date":"2020-12-31","value":88.63,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":5.39,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit1.03M1.33M3.59M6.51M18.91M[{"date":"2020-12-31","value":5.44,"profit":true},{"date":"2021-12-31","value":7.06,"profit":true},{"date":"2022-12-31","value":19.01,"profit":true},{"date":"2023-12-31","value":34.46,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses43.40M58.55M68.75M38.37M49.38M[{"date":"2020-12-31","value":63.12,"profit":true},{"date":"2021-12-31","value":85.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.81,"profit":true},{"date":"2024-12-31","value":71.82,"profit":true}]
Operating Income(42.37M)(57.21M)(65.16M)(31.86M)(30.47M)[{"date":"2020-12-31","value":-4236800000,"profit":false},{"date":"2021-12-31","value":-5721000000,"profit":false},{"date":"2022-12-31","value":-6515900000,"profit":false},{"date":"2023-12-31","value":-3185900000,"profit":false},{"date":"2024-12-31","value":-3047200000,"profit":false}]
Total Non-Operating Income/Expense(7.84M)(6.26M)(3.97M)5.44M4.69M[{"date":"2020-12-31","value":-144.19,"profit":false},{"date":"2021-12-31","value":-115.18,"profit":false},{"date":"2022-12-31","value":-73.03,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":86.2,"profit":true}]
Pre-Tax Income(46.49M)(60.68M)(64.11M)(27.81M)(27.96M)[{"date":"2020-12-31","value":-4649000000,"profit":false},{"date":"2021-12-31","value":-6068200000,"profit":false},{"date":"2022-12-31","value":-6410800000,"profit":false},{"date":"2023-12-31","value":-2781300000,"profit":false},{"date":"2024-12-31","value":-2796000000,"profit":false}]
Income Taxes124.00K117.00K96.00K(78.00K)(197.00K)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.35,"profit":true},{"date":"2022-12-31","value":77.42,"profit":true},{"date":"2023-12-31","value":-62.9,"profit":false},{"date":"2024-12-31","value":-158.87,"profit":false}]
Income After Taxes(46.61M)(60.80M)(64.20M)(27.73M)(27.76M)[{"date":"2020-12-31","value":-4661400000,"profit":false},{"date":"2021-12-31","value":-6079900000,"profit":false},{"date":"2022-12-31","value":-6420400000,"profit":false},{"date":"2023-12-31","value":-2773500000,"profit":false},{"date":"2024-12-31","value":-2776300000,"profit":false}]
Income From Continuous Operations(46.61M)(61.68M)(64.89M)(27.73M)(27.76M)[{"date":"2020-12-31","value":-4661400000,"profit":false},{"date":"2021-12-31","value":-6168000000,"profit":false},{"date":"2022-12-31","value":-6489100000,"profit":false},{"date":"2023-12-31","value":-2773500000,"profit":false},{"date":"2024-12-31","value":-2776300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(46.56M)(60.74M)(64.42M)(28.12M)(27.76M)[{"date":"2020-12-31","value":-4656500000,"profit":false},{"date":"2021-12-31","value":-6074000000,"profit":false},{"date":"2022-12-31","value":-6442400000,"profit":false},{"date":"2023-12-31","value":-2811900000,"profit":false},{"date":"2024-12-31","value":-2776300000,"profit":false}]
EPS (Diluted)(0.92)(0.97)(0.91)(0.35)(0.31)[{"date":"2020-12-31","value":-92,"profit":false},{"date":"2021-12-31","value":-97,"profit":false},{"date":"2022-12-31","value":-91,"profit":false},{"date":"2023-12-31","value":-35,"profit":false},{"date":"2024-12-31","value":-31,"profit":false}]

ProQR Therapeutics BV Ratios

ProQR Therapeutics BV Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

PRQR
Cash Ratio 3.23
Current Ratio 3.36

ProQR Therapeutics BV Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PRQR
ROA (LTM) -24.02%
ROE (LTM) -103.76%

ProQR Therapeutics BV Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PRQR
Debt Ratio Lower is generally better. Negative is bad. 0.54
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.46

ProQR Therapeutics BV Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PRQR
Trailing PE NM
Forward PE NM
P/S (TTM) 9.50
P/B 2.26
Price/FCF NM
EV/R 2.50
EV/Ebitda NM
PEG NM

FAQs

What is ProQR Therapeutics BV share price today?

ProQR Therapeutics BV (PRQR) share price today is $1.455

Can Indians buy ProQR Therapeutics BV shares?

Yes, Indians can buy shares of ProQR Therapeutics BV (PRQR) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PRQR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of ProQR Therapeutics BV be purchased?

Yes, you can purchase fractional shares of ProQR Therapeutics BV (PRQR) via the Vested app. You can start investing in ProQR Therapeutics BV (PRQR) with a minimum investment of $1.

How to invest in ProQR Therapeutics BV shares from India?

You can invest in shares of ProQR Therapeutics BV (PRQR) via Vested in three simple steps:

  • Click on Sign Up or Invest in PRQR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in ProQR Therapeutics BV shares
What is ProQR Therapeutics BV 52-week high and low stock price?

The 52-week high price of ProQR Therapeutics BV (PRQR) is $3.1. The 52-week low price of ProQR Therapeutics BV (PRQR) is $1.07.

What is ProQR Therapeutics BV price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of ProQR Therapeutics BV (PRQR) is

What is ProQR Therapeutics BV price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of ProQR Therapeutics BV (PRQR) is 2.26

What is ProQR Therapeutics BV dividend yield?

The dividend yield of ProQR Therapeutics BV (PRQR) is 0.00%

What is the Market Cap of ProQR Therapeutics BV?

The market capitalization of ProQR Therapeutics BV (PRQR) is $156.96M

What is ProQR Therapeutics BV's stock symbol?

The stock symbol (or ticker) of ProQR Therapeutics BV is PRQR

How Can Investors Use ProQR Therapeutics BV Share Price Data for Long-Term Investment Decisions?

Consider the share price of ProQR Therapeutics BV as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether ProQR Therapeutics BV has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from ProQR Therapeutics BV shares for Indian investors?

When investing in ProQR Therapeutics BV shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the ProQR Therapeutics BV stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare ProQR Therapeutics BV share price with other stocks in the same sector?

Rather than merely checking the share price of ProQR Therapeutics BV and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that ProQR Therapeutics BV stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top